Dr. Abidi Pharmaceuticals’ Latest Milestone in Controlling Acid Reflux and Gastrointestinal Diseases

Dr. Abidi Pharmaceuticals has proudly manufactured and launched a novel medication, Phorize® (scientific name: Vonoprazan), designed for the treatment of gastrointestinal-related conditions, with a primary focus on Gastroesophageal Reflux Disease (GERD). Following Japan and the United States, Iran is among the very first nations globally to produce and provide this highly effective, innovative medication to patients, spearheaded by Dr. Abidi Pharmaceuticals.

Clinical Efficacy and Mechanism of Action (PCAB)

Delivering sustained efficacy, rapid symptom relief, and user-friendly administration (requiring no fasting state)1, Phorize® significantly enhances patients’ quality of life. As a Potassium-Competitive Acid Blocker (PCAB), this advanced medication profoundly inhibits gastric acid secretion, thereby mitigating disruptive reflux symptoms and actively healing esophageal mucosal damage2.

Addressing the High Prevalence of GERD

GERD, or acid reflux, is one of the most prevalent gastrointestinal disorders. Notably, up to 50% of afflicted individuals do not respond adequately to conventional, currently available therapies3. Epidemiological studies indicate that approximately 24 million people in Iran suffer from this condition4.

Manifesting through distressing symptoms such as heartburn and the regurgitation of gastric contents, GERD severely impacts individuals’ daily lives. By effectively and durably controlling gastric acid secretion, Phorize® treats the underlying condition and facilitates the healing of reflux-induced esophageal lesions.

Synergistic Eradication of H. pylori and Cancer Prevention

Another critical clinical indication for Phorize® is its adjunctive use alongside antibiotics for the eradication of Helicobacter pylori (H. pylori) infections2. An estimated 13 million individuals in Iran are infected with this bacterium5.

Extensive clinical studies have established that the effective treatment of H. pylori infections significantly reduces the risk of developing gastric cancer. According to the 2022 report by the World Health Organization (WHO), gastric cancer accounts for the highest incidence and mortality rates among all cancers for both men and women in Iran.

A New Horizon in GI Therapeutics

Phorize® stands at the forefront of a new class of acid-suppressing therapies, heralding novel clinical solutions for the management of acid-related gastrointestinal disorders. Manufactured and commercialized by Dr. Abidi Pharmaceuticals, this medication is fully approved by the Iran Food and Drug Administration (IFDA). Phorize® is a prescription-only (Rx) medication and is readily available in pharmacies nationwide.

 

Ref:

  1. 2024 Nov;167(6):1228-1238.
  2. Vonoprazan Prescribing Information. Revised: 7/2024. Reference ID: 5415220.
  3. Up To Date: Approach to refractory gastroesophageal reflux disease in adults, Sep 2024
  4. BMC Gastroenterol. 2020 Sep 14;20(1):297.
  5. J Res Med Sci. 2018 Jan 29;23:8.

IR-0527-PHR-3469-PR